Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting
– The combination of intratumoral sotigalimab and systemic pembrolizumab was well-tolerated and demonstrated an improved…
G6 Hospitality Signs Development Agreement for New Studio 6 Plus in Marshall, Illinois
ZenaTech Unveils its Proprietary AI Software Suite Designed to Accelerate Land Survey Delivery for Drone as a Service Commercial, Municipal and Infrastructure Clients